Empagliflozin's role in early tubular protection for type 2 diabetes patients.

IF 6 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Medicine Pub Date : 2024-07-31 DOI:10.1186/s10020-024-00881-0

Chuangbiao Zhang, Weiwei Ren, Xiaohua Lu, Lie Feng, Jiaying Li, Beibei Zhu

{"title":"Empagliflozin's role in early tubular protection for type 2 diabetes patients.","authors":"Chuangbiao Zhang, Weiwei Ren, Xiaohua Lu, Lie Feng, Jiaying Li, Beibei Zhu","doi":"10.1186/s10020-024-00881-0","DOIUrl":null,"url":null,"abstract":"Background: Patients with type 2 diabetes often face early tubular injury, necessitating effective treatment strategies. This study aimed to evaluate the impact of the SGLT2 inhibitor empagliflozin on early tubular injury biomarkers in type 2 diabetes patients with normoalbuminuria.Methods: A randomized controlled clinical study comprising 54 patients selected based on specific criteria was conducted. Patients were divided into an intervention group (empagliflozin, n = 27) and a control group (n = 27) and treated for 6 weeks. Tubular injury biomarkers KIM-1 and NGAL were assessed pre- and post-treatment.Results: Both groups demonstrated comparable baseline characteristics. Post-treatment, fasting and postprandial blood glucose levels decreased similarly in both groups. The intervention group exhibited better improvements in total cholesterol, low-density lipoprotein, and blood uric acid levels. Renal function indicators, including UACR and eGFR, showed greater enhancements in the intervention group. Significant reductions in KIM-1 and NGAL were observed in the intervention group.Conclusion: Treatment with empagliflozin in type 2 diabetes patients with normoalbuminuria led to a notable decrease in tubular injury biomarkers KIM-1 and NGAL. These findings highlight the potential of SGLT2 inhibitors in early tubular protection, offering a new therapeutic approach.","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":null,"pages":null},"PeriodicalIF":6.0000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293177/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s10020-024-00881-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Patients with type 2 diabetes often face early tubular injury, necessitating effective treatment strategies. This study aimed to evaluate the impact of the SGLT2 inhibitor empagliflozin on early tubular injury biomarkers in type 2 diabetes patients with normoalbuminuria.

Methods: A randomized controlled clinical study comprising 54 patients selected based on specific criteria was conducted. Patients were divided into an intervention group (empagliflozin, n = 27) and a control group (n = 27) and treated for 6 weeks. Tubular injury biomarkers KIM-1 and NGAL were assessed pre- and post-treatment.

Results: Both groups demonstrated comparable baseline characteristics. Post-treatment, fasting and postprandial blood glucose levels decreased similarly in both groups. The intervention group exhibited better improvements in total cholesterol, low-density lipoprotein, and blood uric acid levels. Renal function indicators, including UACR and eGFR, showed greater enhancements in the intervention group. Significant reductions in KIM-1 and NGAL were observed in the intervention group.

Conclusion: Treatment with empagliflozin in type 2 diabetes patients with normoalbuminuria led to a notable decrease in tubular injury biomarkers KIM-1 and NGAL. These findings highlight the potential of SGLT2 inhibitors in early tubular protection, offering a new therapeutic approach.

查看原文本刊更多论文

Empagliflozin 对 2 型糖尿病患者早期肾小管保护的作用。

背景：2型糖尿病患者常常面临早期肾小管损伤，因此需要有效的治疗策略。本研究旨在评估SGLT2抑制剂empagliflozin对正常白蛋白尿2型糖尿病患者早期肾小管损伤生物标志物的影响：根据特定标准筛选出54名患者，进行随机对照临床研究。患者被分为干预组（empagliflozin，n = 27）和对照组（n = 27），接受为期6周的治疗。对治疗前后的肾小管损伤生物标志物KIM-1和NGAL进行评估：结果：两组的基线特征相当。治疗后，两组的空腹血糖和餐后血糖水平下降相似。干预组在总胆固醇、低密度脂蛋白和血尿酸水平方面有更好的改善。干预组的肾功能指标（包括 UACR 和 eGFR）改善幅度更大。干预组的 KIM-1 和 NGAL 显著降低：结论：对正常白蛋白尿的2型糖尿病患者使用empagliflozin治疗可显著降低肾小管损伤生物标志物KIM-1和NGAL。这些发现凸显了 SGLT2 抑制剂在早期肾小管保护方面的潜力，为治疗提供了一种新方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Medicine 医学-生化与分子生物学

CiteScore

8.60

自引率

0.00%

发文量

137

审稿时长

1 months

期刊介绍： Molecular Medicine is an open access journal that focuses on publishing recent findings related to disease pathogenesis at the molecular or physiological level. These insights can potentially contribute to the development of specific tools for disease diagnosis, treatment, or prevention. The journal considers manuscripts that present material pertinent to the genetic, molecular, or cellular underpinnings of critical physiological or disease processes. Submissions to Molecular Medicine are expected to elucidate the broader implications of the research findings for human disease and medicine in a manner that is accessible to a wide audience.